Article Text

PDF
THU0198 Patient Evaluations of Autoinjectors for Delivery of Subcutaneous Golimumab for Treatment of Rheumatoid Arthritis
  1. H. Schulze-Koops1,
  2. R. Giacomelli2,
  3. W. Samborski3,
  4. S. Rednic4,
  5. M. Herold5,
  6. R. Yao6,
  7. M. Govoni7,
  8. N. Vastesaeger8,
  9. H. H. Weng6
  1. 1Rheumatology, University of Munich, Munich, Germany
  2. 2Rheumatology, Università degli Studi dell’Aquila, L’Aquila, Italy
  3. 3Rheumatology, Ortopedyczno-Rehabilitacyjny Szpital, Wielkopolskie, Poland
  4. 4Rheumatology Clinic, University of Medicine & Pharmacy, Cluj-Napoca, Romania
  5. 5Rheumatology, Medical University of Innsbruck, Innsbruck, Austria
  6. 6Merck Sharp and Dohme, Kenilworth, United States
  7. 7Merck Sharp and Dohme, Rome, Italy
  8. 8Immunology, Merck Sharp and Dohme, Brussels, Belgium

Abstract

Background Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional impairment in the joints of the hand and fingers. An autoinjector designed to account for RA patient disability may improve patient satisfaction.

Objectives To measure the acceptability, ease of use, and preferences for use of a SmartJect autoinjector for SC GLM administration; effects of patient age and functional impairment were evaluated.

Methods GO-MORE was an open-label, multinational, prospective study in biologic-naïve patients with active RA (DAS28-ESR ≥3.2). Patients self-injected 50-mg SC GLM once monthly for 6 months. At months 4 and 6, patients reported their use preferences and opinions of the autoinjector device on a questionnaire. Responses were analyzed descriptively. Effects of patient age and functional impairment on responses were evaluated.

Results Overall, the vast majority of patients found the autoinjector to be easy to use, to cause mild or no discomfort, and to cause mild or no pain (table). At month 6, most of the efficacy-evaluable patients reported they preferred to self-inject in the thigh (75.2%; 1563/2077), followed by the abdomen (17.5%; 363/2077) and the upper arm (7.3%; 151/2077). More than 85% of patients indicated that they used their right hand for self-injection. More than 95% of patients were sure or very sure that when they used the autoinjector, the treatment had been fully injected; and 92.1% were satisfied or very satisfied with the monthly autoinjection frequency. Responses did not differ by patient age group. Patients with minimal or no functional impairment (HAQ-DI ≤0.5) at baseline tended to have more favorable responses, including greater ease of injection and less pain with injection, than those with functional impairment. At month 6, the overall self-injection experience was considered extremely favorable by 53.7% and favorable by 39.5% of patients without impairment and extremely favorable by 42.5% and favorable by 49.1% of patients with impairment.

Conclusions Most patients had very favorable evaluations of the SmartJect autoinjector device for GLM, reporting it to be easy to use, with minimal pain or discomfort upon injection and satisfactory administration frequency.

Disclosure of Interest H. Schulze-Koops Consultant for: Abbott, Actelion, Biotest, BMS, Chugai, Essex, GSK, MSD, Medac, Merck, Mundai Pharma, Novartis, Nycomed, Pfizer, Roche, UCB., R. Giacomelli: None Declared, W. Samborski: None Declared, S. Rednic: None Declared, M. Herold: None Declared, R. Yao Employee of: Merck, M. Govoni Employee of: Merck, N. Vastesaeger Employee of: Merck, H. Weng Employee of: Merck

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.